BusinessBioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten DiseaseBy Nasdaq OMXSep 15, 2016, 12:38 PM UTC
BusinessBioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual MeetingBy Nasdaq OMXSep 8, 2016, 8:30 AM UTC
BusinessBioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten DiseaseBy Nasdaq OMXSep 6, 2016, 8:06 PM UTC
BusinessBioMarin Announces Positive Data From Cerliponase Alfa Program for Treatment of CLN2 Disease, a Form of Batten Disease, at 12th Annual WORLDSymposium(TM) 2016By Nasdaq OMXMar 3, 2016, 12:05 AM UTC
